Formyl peptide receptor 2: a potential therapeutic target for inflammation-related diseases
- PMID: 40102363
- DOI: 10.1007/s43440-025-00704-x
Formyl peptide receptor 2: a potential therapeutic target for inflammation-related diseases
Abstract
Formyl peptide receptor 2 (FPR2) is a G protein-coupled receptor with seven transmembrane domains, widely distributed in human cells. It plays a crucial role in inflammation-related diseases. Known for its "double-edged sword" nature, FPR2 can bind a variety of exogenous and endogenous ligands, mediating both pro-inflammatory and anti-inflammatory responses in tissues such as eyes, liver, joints, lungs, nerves, and blood vessels. FPR2's bioactivities are regulated by a complex network of genes and signaling pathways. However, the precise regulatory mechanisms governing its functions in different inflammatory conditions are still not well understood. This review summarizes the FPR2's activities in various inflammation-related diseases and looks into its potential as a therapeutic target. This review highlights recent advances in developing exogenous agonists for FPR2 and discusses receptor expression across species to support nonclinical research. Overall, this review aims to clarify FPR2's role in inflammation and provide insights for the development of new drugs against inflammatory diseases.
Keywords: Endogenous ligands; Exogenous agonists; Formyl peptide receptor 2; Inflammatory diseases; Therapeutic potential.
© 2025. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests.
Similar articles
-
Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.Eur J Med Chem. 2021 Mar 5;213:113167. doi: 10.1016/j.ejmech.2021.113167. Epub 2021 Jan 12. Eur J Med Chem. 2021. PMID: 33486199 Review.
-
Formyl peptide receptor 2 is an emerging modulator of inflammation in the liver.Exp Mol Med. 2023 Feb;55(2):325-332. doi: 10.1038/s12276-023-00941-1. Epub 2023 Feb 7. Exp Mol Med. 2023. PMID: 36750693 Free PMC article. Review.
-
Biased allosteric modulation of formyl peptide receptor 2 leads to distinct receptor conformational states for pro- and anti-inflammatory signaling.Pharmacol Res. 2020 Nov;161:105117. doi: 10.1016/j.phrs.2020.105117. Epub 2020 Aug 5. Pharmacol Res. 2020. PMID: 32768626
-
Insights into the Activation Mechanism of the ALX/FPR2 Receptor.J Phys Chem Lett. 2020 Nov 5;11(21):8952-8957. doi: 10.1021/acs.jpclett.0c02052. Epub 2020 Oct 8. J Phys Chem Lett. 2020. PMID: 33030905
-
Treating neutrophilic inflammation in COPD by targeting ALX/FPR2 resolution pathways.Pharmacol Ther. 2013 Dec;140(3):280-9. doi: 10.1016/j.pharmthera.2013.07.007. Epub 2013 Jul 21. Pharmacol Ther. 2013. PMID: 23880288 Review.
Cited by
-
Novel Pyrrolidinone Urea as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.ACS Med Chem Lett. 2025 Apr 21;16(5):756-757. doi: 10.1021/acsmedchemlett.5c00196. eCollection 2025 May 8. ACS Med Chem Lett. 2025. PMID: 40365412
-
Bioactive Compounds as Modulators of N-Formyl Peptide Signaling in Chronic Diseases.Molecules. 2025 Jul 16;30(14):2981. doi: 10.3390/molecules30142981. Molecules. 2025. PMID: 40733247 Free PMC article. Review.
References
-
- Bernardette Martínez-Rizo A, Fosado-Rodríguez R, César Torres-Romero J, César Lara-Riegos J, Alberto Ramírez-Camacho M, Ly Arroyo Herrera A, et al. Models in vivo and in vitro for the study of acute and chronic inflammatory activity: a comprehensive review. Int Immunopharmacol. 2024;135:112292. - PubMed - DOI